HopeStage
Back to all studies
CompletedNCT04181736

Biomarker-Guided Support for Cognitive Difficulties in Depression

About this titleRead the official source — NCT04181736
Medication studyAges 18–69United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 69 years.

Listed locations
Palo AltoSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 14, 2022
Recruitment status
Completed
Enrollment listed in the registry
28
Sponsor
Stanford University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 69 Years
Official registry ID
NCT04181736
Official title
Show the full official title

Precision Mental Health: Evaluating Biotype-guided Interventions for Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Palo Alto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Stanford University, a university.

Did this study involve medication?

Yes. The study involved medication, including Guanfacine Tablets.

Who was this study for?

Listed age limits: 18 years to 69 years.

Want to explore more studies?

Explore studies